A detailed history of Stonnington Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Stonnington Group, LLC holds 35,845 shares of BMY stock, worth $2.07 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
35,845
Previous 38,241 6.27%
Holding current value
$2.07 Million
Previous $2.75 Million 9.71%
% of portfolio
0.65%
Previous 0.77%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 14, 2023

SELL
$65.71 - $74.53 $157,441 - $178,573
-2,396 Reduced 6.27%
35,845 $2.48 Million
Q4 2022

Jan 11, 2023

SELL
$68.48 - $81.09 $287,410 - $340,334
-4,197 Reduced 9.89%
38,241 $0
Q3 2022

Oct 20, 2022

BUY
$0.13 - $76.84 $39 - $23,359
304 Added 0.72%
42,438 $3.02 Million
Q2 2022

Jul 08, 2022

BUY
$72.62 - $79.98 $256,203 - $282,169
3,528 Added 9.14%
42,134 $3.17 Million
Q1 2022

Apr 12, 2022

SELL
$61.48 - $73.72 $11.3 Million - $13.6 Million
-184,439 Reduced 82.69%
38,606 $2.95 Million
Q4 2021

Jan 12, 2022

SELL
$53.63 - $62.52 $212,374 - $247,579
-3,960 Reduced 11.05%
31,864 $2.09 Million
Q4 2021

Jan 12, 2022

BUY
$53.63 - $62.52 $10.3 Million - $12 Million
191,181 Added 599.99%
223,045 $14.6 Million
Q3 2021

Oct 12, 2021

SELL
$59.17 - $69.31 $210,645 - $246,743
-3,560 Reduced 9.04%
35,824 $2.05 Million
Q2 2021

Jul 09, 2021

BUY
$61.91 - $67.42 $191,921 - $209,002
3,100 Added 8.54%
39,384 $2.63 Million
Q1 2021

May 21, 2021

BUY
$59.34 - $66.74 $2.15 Million - $2.42 Million
36,284 New
36,284 $2.34 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Stonnington Group, LLC Portfolio

Follow Stonnington Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonnington Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonnington Group, LLC with notifications on news.